Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study-Reference-Cited by-同舟云学术

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study

Published:2018-11-15 Issue:2 Volume:15 Page:317-326
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Kim Ki Hwan¹,Kim Chun Soo²,Kim Hwang Min³^ORCID,Kim Jong-Duck⁴,Ma Sang Hyuk⁵,Kim Dong Ho⁶,Hwang Pyoung-Han⁷,Han Ji-Whan⁸,Lee Taek-Jin⁹^ORCID,Kim Joon Hyung¹⁰^ORCID,Karkada Naveen¹¹,Mesaros Narcisa¹¹,Sohn Woo-Yun¹⁰,Kim Jong-Hyun¹²

Affiliation:

1. Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea Incheon, The Republic of Korea

2. Keimyung University School of Medicine, Daegu, The Republic of Korea

3. Yonsei University Wonju College of Medicine, Wonju, The Republic of Korea

4. Wonkwang University Hospital, Iksan, The Republic of Korea

5. Changwon Fatima Hospital, Changwon, The Republic of Korea

6. Korea Cancer Center Hospital, Seoul, The Republic of Korea

7. Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, The Republic of Korea

8. Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Uijeongbu, The Republic of Korea

9. Bundang CHA Hospital, Seongnam, The Republic of Korea

10. GSK, Seoul, The Republic of Korea

11. GSK, Wavre, Belgium